Quantum BioPharma (NASDAQ: QNTM) announced the results of its Nov. 10, 2026, annual general and special meeting of shareholders and the closing of a non-brokered private placement of 26 Class A multiple voting shares on Nov. 9. Shareholders elected all five director nominees, reappointed MNP LLP as auditor and approved several resolutions, including authorization to issue additional Class A multiple voting shares to maintain up to 70% aggregate voting power, a 2026 omnibus equity incentive plan, a potential share consolidation at a ratio of up to 10-for-1 and a potential corporate name change. The board retains discretion over implementing the authorized measures.
The company also issued 26 Class A multiple voting shares at C$3.11 per share, generating gross proceeds of C$80.86. Xorax Family Trust, associated with CEO Zeeshan Saeed, and Fortius Research and Trading Corp., controlled by director Anthony Durkacz, each acquired 13 shares. Following the placement, the aggregate voting power of Class A multiple voting shares increased from approximately 57.01% to 68.22%. The transaction was completed under shareholder authorization granted in 2025, with proceeds designated for general working capital purposes.
At a glance
- Company
- Quantum BioPharma Ltd.
- Ticker
- NASDAQ: QNTM
- Announcement
- Financing
Key figures
- Class A multiple voting shares issued
- 26
- Price per share
- C$3.11
- Gross proceeds
- C$80.86
- Aggregate voting power after placement
- 68.22%
- Potential consolidation ratio
- up to 10-for-1
- Authorized aggregate voting power
- up to 70%
People
- Zeeshan SaeedCEO
- Anthony DurkaczDirector
To view the full press release, visit https://ibn.fm/UagXR
About Quantum BioPharma Ltd.
Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Corporate Communications
IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]
Terms explained
- Non-brokered private placement
- A company’s sale of securities to selected investors without using an underwriting investment dealer to arrange and distribute the offering.
- Multiple voting shares
- A class of shares that carries more votes per share than another class, giving its holders greater influence over shareholder decisions relative to their economic ownership.
- Aggregate voting power
- The combined share of votes that a person, group or class of shares can cast on matters put to shareholders.
- Share consolidation
- A corporate action that replaces a given number of existing shares with fewer new shares. It changes the share count but does not, by itself, change a shareholder’s proportional ownership.
- Omnibus equity incentive plan
- A company plan that brings different forms of share-based compensation, such as options or awards, under a common set of rules for eligible participants.
SEC filings
Earlier from Quantum BioPharma Ltd.
- Quantum BioPharma (NASDAQ: QNTM) Draws ‘Men’s Fitness’ Spotlight as Unbuzzd Trial Shows Early Promise
- Quantum BioPharma (NASDAQ: QNTM) Enlists Thermo Fisher’s Clinical Research Business to Launch Phase 2 Lucid-MS Trial
- Quantum BioPharma (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
- Quantum BioPharma (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing
- Quantum BioPharma (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
